Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.25 Consensus Price Target from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been given an average rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $6.25.

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, April 25th. The Goldman Sachs Group lowered their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. Finally, Needham & Company LLC lowered their target price on shares of Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th.

Institutional Trading of Esperion Therapeutics

Several large investors have recently bought and sold shares of the company. Summit Financial LLC raised its stake in shares of Esperion Therapeutics by 18.2% in the 4th quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 7,150 shares in the last quarter. Private Advisor Group LLC raised its stake in Esperion Therapeutics by 33.2% during the first quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company’s stock valued at $58,000 after buying an additional 10,000 shares in the last quarter. Invesco Ltd. lifted its holdings in Esperion Therapeutics by 15.5% during the 4th quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 13,101 shares during the last quarter. Two Sigma Advisers LP increased its holdings in shares of Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after acquiring an additional 16,100 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Esperion Therapeutics by 15.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 123,896 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 16,404 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Price Performance

NASDAQ:ESPR opened at $1.17 on Wednesday. The firm has a market capitalization of $231.89 million, a PE ratio of -1.83 and a beta of 0.67. The business’s fifty day moving average price is $0.95 and its 200 day moving average price is $1.67. Esperion Therapeutics has a 12 month low of $0.69 and a 12 month high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The business had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million. As a group, equities analysts anticipate that Esperion Therapeutics will post -0.29 EPS for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.